Compare SPH & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPH | MNKD |
|---|---|---|
| Founded | 1945 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 1996 | 2004 |
| Metric | SPH | MNKD |
|---|---|---|
| Price | $16.54 | $3.34 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $8.69 |
| AVG Volume (30 Days) | 186.4K | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.63% | N/A |
| EPS Growth | ★ 42.11 | N/A |
| EPS | ★ 2.48 | N/A |
| Revenue | ★ $1,432,518,000.00 | $348,966,000.00 |
| Revenue This Year | $2.06 | $35.81 |
| Revenue Next Year | $1.64 | $11.89 |
| P/E Ratio | $6.65 | ★ N/A |
| Revenue Growth | 7.94 | ★ 22.23 |
| 52 Week Low | $16.34 | $2.23 |
| 52 Week High | $20.80 | $6.51 |
| Indicator | SPH | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 31.17 | 32.17 |
| Support Level | $16.53 | $3.30 |
| Resistance Level | $17.86 | $4.29 |
| Average True Range (ATR) | 0.29 | 0.18 |
| MACD | -0.05 | -0.05 |
| Stochastic Oscillator | 19.67 | 14.55 |
Suburban Propane Partners LP distributes propane, renewable propane, renewable natural gas (RNG), fuel oil, refined fuels, and markets natural gas and electricity in deregulated markets. It produces and invests in low-carbon fuel alternatives. The company installs and services home comfort heating and ventilation equipment and distributes fuel oil, kerosene, diesel, and gasoline to about 25,000 residential and commercial customers mainly in the U.S. northeast. It operates three segments: Propane, Fuel Oil and Refined Fuels, and Natural Gas and Electricity, with the Propane segment generating the majority of revenue. Propane, a by-product of natural gas processing and petroleum refining, is a clean-burning energy source known for transportability and ease of use.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.